Private Market View

Raffles PharmaTech

Huizhou, China · Founded 2011 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$14.1M
Last round

Key facts

  • It has raised $14.1M; the latest was Later Stage VC in Jun 2025.
  • Notable investors include TopoScend Capital, Huizhou Dayawan Petrochemical Industrial Park Investment, Realharmony Capital, Winzac Capital.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 4 names
  • ·Watchlist + deal alerts for Raffles PharmaTech
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Raffles PharmaTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Raffles PharmaTech

Developer of value added active pharmaceutical ingredients and intermediates intended to support development of new pharmaceuticals. The company is a tech enterprise that focuses on development, manufacturing and sales of value added active pharmaceutical ingredients, intermediates, and small molecule process development and manufacturing services, enabling pharmaceuticals and chemical industries to ensures precision, reliability, and efficiency in every stage of chemical development and production.

Sector
Healthcare
HQ
Huizhou, China
Founded
2011
Employees
200
Ownership
Privately Held (backing)
PA Mark — not yet priced

Raffles PharmaTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Raffles PharmaTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Raffles PharmaTech in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.